TFFP (tffpharma.com) Market Value to Book Value Ratio

Official company branding of TFF Pharmaceuticals Inc. (TFFP)

The strategic growth of TFF Pharmaceuticals (TFFP) relies on partnerships with vaccine developers through licensing agreements. The company's current P/BV multiple visualizes this trend, where 0.07 shapes the current metric. Revenues are based on royalties from Big Pharma for the use of patents, while success depends on the bioavailability of powder forms and the number of drug delivery contracts.

TFFP TFF Pharmaceuticals, Inc: Market Value to Book Value in the range 07/04/2022 - 12/21/2024

Financial and market metric breakdowns for TFF Pharmaceuticals Inc. (TFFP)

- price and consensus price forecast:
Price Chart TFF Pharmaceuticals|TFFP - Forecast Levels Chart
- market capitalization data:
Market Value TFF Pharma|TFFP - Full Business Value
- book capitalization data:
Book Value per Share TFF Pharmaceuticals|TFFP - Accounting Value of Company|Market Capitalization to Book Value Ratio tffpharma.com|TFFP - Company Total Assets
- debt and liquidity data:
Debt to Equity TFF Pharmaceuticals|TFFP - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity TFF Pharma|TFFP - Company Total Debt|Debts to Book Capitalization TFF Pharma
Initial company analysis:TFF Pharmaceuticals - TFFP
Original product of TFF Pharma

This ratio determines the strategic control premium by comparing the current market value of the business with its book value. The metric's dynamics reflect the real-time assessment of investors to shifting fundamental expectations between reporting periods. By analyzing the deviation of market valuation from book value, one can identify the extent of the overpayment for assets. For TFF Pharmaceuticals (TFFP), a high premium is driven by the potential of thin-film freezing technology. The indicator's growth will depend on the success of voriconazole clinical trials and the execution of licensing agreements.

Main competitors

Market Value to Book Value Ratio Haleon plc (HLN)|KVUE (kenvue.com) - Market Capitalization to Net Assets|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com (PCRX)|ARS Pharmaceuticals, Inc. (SPRY) - Market Cap to Net Assets Ratio|Market Value to Book Value TBPH (Theravance Biopharma Inc)|AQST: Market Value to Book Value Ratio|SCPH - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tectonic TECX|TNXP - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio sxtchina.com SXTC|Eupraxia Pharmaceuticals Inc. (EPRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio BHST (BioHarvest)|Market-to-Book Ratio EXOZ|Oramed Pharmaceuticals (ORMP) - Market Value to Book Value Ratio|Market Value to Book Value enterabio.com ENTX|Market Cap to Net Assets Ratio MindWalk Holdings Inc. (HYFT)|Market Cap to Book Value Multiple ABVC BioPharma Inc. ABVC|Market Capitalization to Book Value Ratio Cumberland Pharma|QNTM - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio FibroGen, Inc. (FGEN)|Market Capitalization to Net Assets telomirpharma.com|RANI - Market Cap to Net Assets Ratio|Market Value to Book Value SNYR|RLYB - Market Value to Book Value Ratio|Market Capitalization to Net Assets lexariabioscience.com (LEXX)|Market Capitalization to Book Value Ratio Pulmatrix, Inc.|Market Value to Book Value Pheton Holdings Limited PTHL|Aptorum - Market Capitalization to Book Value Ratio|LYRA: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Impact BioMedical IBO|TNFA (TNF Pharmaceuticals, Inc.) - Market Value to Book Value|Market Value to Book Value Ratio YCBD|Market Cap to Net Assets Ratio painreform.com|Market Capitalization to Book Value Ratio CYTO|Market Capitalization to Book Value Ratio Lipella Pharmaceuticals Inc (LIPO)|Optinose - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Pieris Pharma PIRS|PROC (Procaps Group S.A.) - Market Capitalization to Book Value Ratio|petrospharma.com (PTPI) - Market-to-Book Ratio|QLI: Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Acelyrin Inc.